Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
Queen Mary University Of London maintains a portfolio focused on the Biotechnology & Pharmaceuticals technology area. The university currently faces 8 pending office actions, which are distributed among 8 distinct examiners. This distribution shows that no examiner is handling more than 1 pending matter for the institution at this time.
The prosecution activity spans 6 distinct art units, suggesting a range of technical subject matter within the Biotechnology & Pharmaceuticals sector. This breadth requires the university to navigate various examination standards across multiple specialized groups at the patent office. Practitioners should prepare for diverse examiner perspectives given this organizational spread.
HUANG, DAVID Z is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because the total of 8 pending office actions is spread across 8 distinct examiners, HUANG, DAVID Z shares the pending workload with the other distinct examiners. This distribution requires managing relationships across 6 distinct art units.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (12%) |
| §101 + other | 1 (12%) |
| §103 only | 2 (25%) |
| §112 only | 1 (12%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUANG, DAVID Z | 1 | 80.3% | +13.3% |
| FAUST, AMBER KATHLEEN | 1 | 60.6% | +53.3% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.2% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
| VANN-OJUEKAIYE, KENDRA RAYCHELL | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 73d overdue |
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 3d overdue |
| 18850223 | FORCE SENSOR | HUANG, DAVID Z | — |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
| 17628951 | METHODS FOR DIAGNOSING CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 73d overdue |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 38d overdue |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 8d overdue |
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 3d overdue |
| 18156184 | Oncolytic Vaccinia Virus | NGUYEN, QUANG | 20d |
| 18850223 | FORCE SENSOR | HUANG, DAVID Z | — |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1674 | 1 |
| 1614 | 1 |
| 1619 | 1 |
| 1631 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18850223 | FORCE SENSOR | HUANG, DAVID Z | — | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18570043 | Treatment of Inflammatory Conditions or Diseases | FAUST, AMBER KATHLEEN | — | §102§103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 18365369 | Method for Determining Prognosis of Cancer | AEDER, SEAN E | 1642 | §101 | Non-Final OA | 3d overdue | Pending | Aug 04, 2023 |
| 18344502 | ROR2 INHIBITORS AND USE THEREOF IN TREATING AND/OR PREVENTING CARTILAGE LOSS | MCCOLLUM, ANDREA K | 1674 | §102§112 | Final Rejection | 73d overdue | Pending | Jun 29, 2023 |
| 18268933 | Composition Comprising Calcium Orthophosphate and a Bioactive Glass Comprising Fluorine | LIU, TRACY | 1614 | §103 | Final Rejection | 38d overdue | Pending | Jun 21, 2023 |
| 18256752 | SUSTAINED RELEASE FORMULATIONS OF CRYSTALLINE DRUGS | KASSA, TIGABU | 1619 | §103 | Final Rejection | 8d overdue | Pending | Jun 09, 2023 |
| 18156184 | Oncolytic Vaccinia Virus | NGUYEN, QUANG | 1631 | §112 | Final Rejection | 20d | Pending | Jan 18, 2023 |
| 17628951 | METHODS FOR DIAGNOSING CANCER | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §101§103§112 | Non-Final OA | — | Pending | Jan 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial